Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18305004 | 0.90 | LMNA (0.49) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL14492521 | 0.83 | NPSR1 (0.40) | LMNAGAAKDM4EALDH1A1NPSR1 | |
| SCHEMBL31207901 | 0.83 | LMNA (0.44) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL31207902 | 0.83 | LMNA (0.44) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL7849089 | 0.83 | KDM4E (0.58) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL1298575 | 0.83 | LMNA (0.44) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL30726179 | 0.80 | SMN1; SMN2 (0.42) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL26620710 | 0.80 | SMN1; SMN2 (0.42) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL11826677 | 0.80 | SMN1; SMN2 (0.49) | LMNAGAAMAPTKDM4EALDH1A1 | |
| SCHEMBL30726180 | 0.79 | LMNA (0.40) | LMNAGAAMAPTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | WELLS THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA SAN DIEGO, INC. | 2022-09-29 | — | — | US | disclosed |
| EP-3825316-A1 | FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2021-05-26 | — | — | EP | disclosed |
| EP-3489236-B1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICALS CO (JP) | 2020-09-30 | — | — | EP | disclosed |
| EP-3489236-A1 | PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES | Takeda Pharmaceutical Company Limited (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-2902392-B1 | Fused heteroaromatic pyrrolidinones as syk inhibitors | TAKEDA PHARMACEUTICALS CO (JP) | 2018-10-17 | — | — | EP | disclosed |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | CALITHERA BIOSCIENCES, INC. | 2018-05-24 | — | — | US | disclosed |
| EP-2900639-B1 | BICYCLIC DIHYDROPYRIDONE KINASE INHIBITORS | PORTOLA PHARM INC (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9533986-B2 | Bicyclic dihydropyridone kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2017-01-03 | — | — | US | disclosed |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-26 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | WARNER-LAMBERT COMPANY LLC | 2009-09-10 | — | — | US | disclosed |
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | WARNER-LAMBERT COMPANY LLC | 2008-10-16 | — | — | US | disclosed |
| EP-1749004-B1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER LAMBERT CO (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1682532-B1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | WARNER LAMBERT CO (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1749004-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | Warner-Lambert Company LLC (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1682532-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE-3-KINASES (PI3K) | Warner-Lambert Company LLC (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005105801-A1 | PYRROLYL SUBSTITUTED PYRIDO[2,3-D]PYRIMIDIN-7-ONES AND DERIVATIVES THEREOF AS THERAPEUTIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005042519-A1 | PYRIMIDINES AS INHIBITORS OF PHOSPHOINOSITIDE -3-KINASES (PI3K) | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227587-A1 | Pyrimidines as inhibitors of phosphoinositide-3-kinases (PI3K) | PIK3CA, PIK3CD, PIK3R5 | LMNA 4458/4885GAA 2741/4885MAPT 4425/4885 |
| US-20220306634-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LMNA 4615/4885GAA 2316/4885MAPT 4621/4885 |
| US-20080255162-A1 | Pyrrolyl Substituted Pyrido[2,3-D]Pyrimidin-7-Ones and Derivatives Thereof as Therapeutic Agents | TYMS, DPYD, TYMP | LMNA 4454/4885GAA 4368/4885MAPT 4375/4885 |
| US-20180141951-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LMNA 4615/4885GAA 2316/4885MAPT 4621/4885 |
| US-20150336964-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LMNA 4615/4885GAA 2316/4885MAPT 4621/4885 |
| US-20230295171-A1 | FUSED HETEROAROMATIC PYRROLIDINONES | SYK, ZAP70, LYN | LMNA 4615/4885GAA 2316/4885MAPT 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.